The Patent Finder

Terms ending in 2038

Sandoz AG

Every in-force patent on Sandoz AG's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,040,986Crystalline Forms of Cabotegravir Sodium
In force
 · High confidence
Viiv Healthcare UK (No. 3) LimitedIn forceHigh confidence
US 11,037,047Improvements in counting devices
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 10,966,979Amorphous Solid Dispersion Of An Orally Available Gonadotropin-Releasing Hormone Receptor Antagonist
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 11,192,860Co-Crystal of an Orally Available Hif Prolyl Hydroxylase Inhibitor
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 11,851,666Multi-Copy Gene Protein Expression System
In force
 · High confidence
Novartis Pharma AGIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Sandoz AG.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited